The New Generation of Sleep Medications: What to Know About Orexin Receptor Antagonists
Insomnia is one of the most common problems people bring to their doctor, and for good reason. Chronic poor sleep affects mood, focus, metabolic health, and even long-term brain health. First and foremost, the most effective treatments are not medications at all. Behavioral changes, sleep hygiene, and cognitive behavioral therapy for insomnia (CBT-I) remain the gold standard because they address the underlying patterns that keep people awake. Simply taking a pill may be easy, but truly impactful and lasting improvement takes work.
Still, many people either cannot access CBT-I or need additional help. For decades, the main prescription options have been drugs that directly depress the brain to induce sleep. These medications can work, but they often come with side effects like grogginess, memory issues, falls, or dependence.
A newer class of medications works very differently. These are the orexin receptor antagonists, often called DORAs or ORAs. They approach sleep by targeting the brain's wakefulness system rather than by pushing the entire nervous system into sedation. Because of that, they offer an important alternative for people who need pharmacologic help but want to avoid many of the drawbacks of older sleep drugs.
What Are Orexin Receptor Antagonists
Orexin is a small signaling molecule produced in the lateral hypothalamus that helps keep you awake. It acts like a switch that keeps the arousal system activated. When orexin levels are high, the brain is more alert. When orexin signaling is blocked, the wakefulness drive quiets down and sleep becomes possible.
DORAs block the receptors that orexin uses to stimulate the wake system. Instead of forcing sedation, they simply remove the wake signal. This tends to produce sleep that feels more natural, easier to wake from, and less cognitively impairing.
Three of these medications are currently FDA-approved: suvorexant, lemborexant, and daridorexant. A fourth, seltorexant, is in late-stage clinical trials.
How They Differ From Older Sleep Medications
Traditional hypnotics such as benzodiazepines and the Z-drugs (zolpidem, eszopiclone, and zopiclone) act by amplifying GABA, the main inhibitory neurotransmitter. This produces sedation, but it also depresses broad areas of the brain. The result can be memory problems, impaired coordination, slowed reaction time, and in older adults a higher risk of falls, fractures, confusion, and next-day impairment.
DORAs do not work on GABA. They reduce wakefulness without causing widespread suppression. This difference in mechanism leads to several important advantages.
Better cognitive safety Multiple trials show that DORAs cause fewer problems with memory, attention, or coordination. In some studies, cognitive testing actually improved compared with placebo, suggesting that normalizing sleep may support daytime function. Head-to-head comparisons show that zolpidem impairs verbal memory, hand-eye coordination, and processing speed during unexpected awakenings, while orexin antagonists do not. This is particularly relevant for parents, caregivers, pilots, physicians on call, and anyone who may need to wake quickly and function safely.
Lower risk of dependence Because they do not work on the same receptors as benzodiazepines, DORAs carry much lower risk of physiological dependence or withdrawal. People do not generally develop tolerance, and stopping the medication does not typically produce rebound insomnia.
Better side effect profile The most common side effects are sleepiness, fatigue, and occasional vivid dreams. These are usually mild. Importantly, DORAs avoid the anticholinergic effects associated with sedating antidepressants and antihistamines, which can contribute to cognitive decline over time.
Contraindications These drugs should not be used in people with narcolepsy, especially narcolepsy with cataplexy. Narcolepsy itself is caused by orexin deficiency, so further blocking orexin signaling can worsen symptoms.
What the Clinical Studies Show
Strong efficacy for both falling asleep and staying asleep Across dozens of randomized controlled trials, orexin antagonists shorten the time it takes to fall asleep, reduce wakefulness during the night, and increase total sleep time. Network meta-analysis suggests they rank among the most effective medication options for multiple sleep parameters.
Better preserved cognition than other hypnotics Studies involving tasks such as memory recall, attention tests, and psychomotor performance show that DORAs maintain performance at doses that promote sleep. In contrast, zolpidem and related drugs produce marked impairment on the same measures at sleep-promoting doses. One large meta-analysis using the Digit Symbol Substitution Test showed that DORAs produced positive scores — indicating preserved or even improved cognitive speed — while zolpidem and zopiclone produced negative scores.
Daridorexant and daytime functioning Daridorexant, the newest FDA-approved DORA, was specifically designed to provide sufficient nighttime coverage without next-day sedation. In phase 3 trials, it improved subjective sleep, objective sleep efficiency, and daytime functioning — a novel finding not previously demonstrated with other sleep medications.
Possible neuroprotective effects Some early work suggests that improving sleep through orexin blockade may reduce amyloid accumulation, neuroinflammation, and other processes involved in Alzheimer's and Parkinson's disease. These findings are preliminary but intriguing, since sleep quality is tightly linked to long-term brain health.
Selective OX2R antagonists Seltorexant, now in phase 3 trials, targets only one of the two orexin receptors. Early evidence suggests it may promote sleep effectively while possibly avoiding certain REM sleep changes associated with dual receptor blockade. It has shown improvements in sleep efficiency and total sleep time with good tolerability in phase 2 studies.
Practical Considerations
Which DORA is the best choice
Each medication differs slightly in how quickly it works and how long it lasts:
Suvorexant — effective for both sleep onset and maintenance
Lemborexant — strong data for staying asleep, with good tolerability
Daridorexant — designed to minimize next-day sedation and improve daytime functioning
For most people, daridorexant and lemborexant offer a balanced profile. Suvorexant remains an option, though it tends to cause more next-morning drowsiness in some users.
What to expect when taking one These drugs do not knock you out. They quiet the wake drive, which leads to a more natural sleep pattern. Most people fall asleep within 30 to 60 minutes of taking them. Sleep tends to feel lighter but more restorative, and it is easier to wake up if needed.
Who might benefit
People with difficulty staying asleep
Individuals with previous problems on zolpidem or benzodiazepines
Older adults concerned about cognitive effects or fall risk
Anyone looking for a safer long-term pharmacologic option
Where This Fits Into an Overall Sleep Plan
Medications should support good sleep, not replace the habits that sustain it. Even the best pills do not fix irregular sleep schedules, late-night screen use, inconsistent wake times, or untreated sleep disorders such as apnea.
DORAs are a meaningful step forward for people who do need medication. They are targeted, effective, and far safer cognitively than the medications many people have relied on for decades. When paired with behavioral strategies, they can be part of a long-term plan that protects sleep quality and supports daytime functioning.
References
Morin CM, Buysse DJ. Management of Insomnia. New England Journal of Medicine. 2024;391(3):247-258.
Uslaner JM, et al. Orexin Receptor Antagonists Differ From Standard Sleep Drugs by Promoting Sleep at Doses That Do Not Disrupt Cognition. Science Translational Medicine. 2013;5(179):179ra44.
Neylan TC, et al. Acute Cognitive Effects of the Hypocretin Receptor Antagonist Almorexant Relative to Zolpidem and Placebo. Sleep. 2020;43(10):zsaa080.
Zhou M, et al. Orexin Dual Receptor Antagonists, Zolpidem, Zopiclone, Eszopiclone, and Cognitive Research: A Comprehensive Dose-Response Meta-Analysis. Frontiers in Human Neuroscience. 2022;16:1029554.
Roch C, et al. Nonclinical Pharmacology of Daridorexant. Psychopharmacology. 2021;238(10):2693-2708.
Mignot E, et al. Safety and Efficacy of Daridorexant in Patients With Insomnia Disorder. The Lancet Neurology. 2022;21(2):125-139.
Yue JL, et al. Efficacy and Tolerability of Pharmacological Treatments for Insomnia in Adults: A Systematic Review and Network Meta-Analysis. Sleep Medicine Reviews. 2023;68:101746.
Panda SP, et al. Role of OX/OXR Cascade in Insomnia and Sleep Deprivation Link Alzheimer's Disease and Parkinson's Disease. Biochemical Pharmacology. 2025;233:116794.
Mesens S, et al. Efficacy and Safety of Seltorexant in Insomnia Disorder. JAMA Psychiatry. 2025.
Dr. Schraga is a concierge physician at Crescendo MD in Portola Valley, California, specializing in preventive and longevity medicine for executives and families in Silicon Valley.
